Findings from the FLAURA2 study, presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, showed that chemotherapy added to osimertinib in the first-line setting significantly increased progression-free survival (PFS) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). However, without data showing an overall survival (OS) benefit, and given increased adverse events, are the results enough to change practice? Panelists H. Jack West, MD, from the City of Hope Comprehensive Cancer Center in the Los Angeles area; Devika Das, MD, from the University of Alabama at Birmingham; and Charu Aggarwal, MD, MPH, from the University of Pennsylvania’s Abramson Cancer Center in Philadelphia, discuss how best to weigh a potential PFS boost against a host of other key considerations. Beyond the FLAURA2 results, the panelists discuss other upcoming findings that are likely to create similar challenging treatment considerations. Read more.